Navigation Links
Anesthetic approach stops pain without affecting motor function
Date:2/1/2010

BOSTON, Mass. - One of the holy grails of local anesthesia is the ability to achieve a long-lasting nerve block that eliminates pain sensation while not affecting motor function. Now, researchers at Children's Hospital Boston have discovered an anesthetic approach that seems to do just that. If it proves to work in humans as well as it did in rats, it could be useful in a variety of medical applications, providing, for example, a local anesthetic for childbirth that would block pain without interfering with the mother's ability to push, or for musculoskeletal disorders in which it is important to maintain mobility.

The discovery was reported in the online Early Edition of the Proceedings of the National Academy of Sciences during the week of February 1.

The researchers, led by Daniel Kohane, MD, PhD, of the Division of Critical Care Medicine at Children's, originally sought only to find an agent that would prolong the anesthetics' effects. They focused on surfactants, a subclass of so-called "chemical permeability enhancers" that enable drugs to spread more easily throughout a tissue.

In testing three kinds of surfactant along with the anesthetics QX-314 and QX-222 (both derivatives of lidocaine), they found that this approach did prolong the sensory block in rats' sciatic nerves, for up to 7 hours or more depending on the surfactant, but didn't prolong motor impairment; in some cases the motor block was absent or of very short duration. In the rats, this meant they were able to tolerate having their paws on a hot plate for long periods, yet still able to balance and bear weight on their legs.

"This was a surprise finding," says Kohane, who also directs the Laboratory for Biomaterials and Drug Delivery (LBDD) at Children's. "What we've discovered really is a new approach; the question now is to figure out the mechanism by which it works and look at the effects of other chemical permeability enhancers."

Kohane speculates that surfactant made the anesthetic better able to penetrate sensory nerves, which have little or none of the fatty coating known as myelin, whereas in motor neurons, which have abundant myelin, the active drug gets trapped in the myelin, never entering the nerve itself.

The lab's next steps will be to explore the effects of different permeability enhancers and examine their safety, since at high doses the drug combination could potentially be toxic to the nerves. The eventual plan is to test the approach in larger animals.

A parallel approach to achieving a pain-specific nerve block was proposed in 2007 by Clifford Woolf, MD, PhD, recently appointed director of the Children's Hospital Boston Program in Neurobiology. Woolf's team combined QXT-314 with capsaicin, which opens cellular gates that are only present in sensory neurons, and achieved pain-specific blocks in rats lasting 2 hours or more.


'/>"/>

Contact: Erin McColgan
erin.mccolgan@childrens.harvard.edu
617-919-3110
Children's Hospital Boston
Source:Eurekalert

Related medicine news :

1. Anesthetic Approach Stops Pain Without Affecting Motor Function
2. General anesthetics lead to learning disabilities in animal models
3. Finding of genetic region controlling cardiovascular sensitivity to anesthetic propofol
4. Mass. General team develops potentially safer general anesthetic
5. Cesarean section: Local anesthetic reduces need for painkillers post-op
6. As Fire Ants Continue to Proliferate, Hospital-Proven Burn Anesthetic Brings Instant Relief for Bites, Stings
7. Milestone Scientific Hosts Second Annual Symposium on Computer-Controlled Local Anesthetic Delivery (C-CLAD)
8. Researchers Create Long-Acting Local Anesthetic
9. Medical study shows epidurals and spinal anesthetics are safer than previously reported
10. MINRAD International, Inc. Announces Termination of RxElite Holdings Inc. as Anesthetics Distributor for the Human Market in United States
11. Common anesthetic induces Alzheimers-associated changes in mouse brains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra Beach, ... journal articles published in Emergency Medicine Practice and Pediatric Emergency Medicine ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions ... initiated cultivation and processing operations at its production facility, and opened its first ... is the manufacturer of a complete system of proactive air and surface purification ...
(Date:6/24/2016)... ... , ... National recruitment firm Slone Partners is pleased to announce ... experience, as Vice President of North American Capital Sales at HTG Molecular . ... sales team in the commercialization of the HTG EdgeSeq system and associated reagents in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: